Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
36 hedge funds and large institutions have $36.7M invested in Dicerna Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 10 closing their positions.
0.41% less ownership
Funds ownership: 56.03% → 55.63% (-0.41%)
10% less capital inflows, than outflows
Capital inflows: $1.68M | Capital outflows: $1.87M
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
20% less funds holding
Funds holding: 45 → 36 (-9)
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EcoR1 Capital
San Francisco,
California
|
+$1.22M |
| 2 |
Bourgeon Capital Management
Darien,
Connecticut
|
+$80.5K |
| 3 |
Renaissance Technologies
New York
|
+$77.7K |
| 4 |
Birchview Capital
Burlington,
Vermont
|
+$63.2K |
| 5 |
Palo Alto Investors
Palo Alto,
California
|
+$61.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.3M |
| 2 |
Virtu KCG Holdings
New York
|
-$96K |
| 3 |
PDT Partners
New York
|
-$86K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$78K |
| 5 |
Morgan Stanley
New York
|
-$77.4K |
DRNA Hedge Fund Activity: Q2 2017 in Review
36 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q2 2017, worth a combined $36.7M — down 7.3% from $39.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of DRNA and 2 opened new positions — a net loss of 8 holders — while 12 trimmed existing stakes and 10 added.
The largest buyer was EcoR1 Capital, adding an estimated $1.22M. The largest seller was Fidelity Investments, cutting an estimated $1.3M.
- 36 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q2 2017, down from 45 in Q1 2017.
- Funds reported $36.7M of Dicerna Pharmaceuticals, Inc. stock for Q2 2017, down 7.3% quarter-over-quarter.
- 2 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q2 2017 and 10 closed out, a net change of -8 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q2 2017 was EcoR1 Capital, an estimated $1.22M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q2 2017 was Fidelity Investments, an estimated $1.3M sold.
Based on aggregated 13F filings for Q2 2017.